Spotlight On... J&J chief shells out $9M for Manhattan condo; J&J goes to court over talcum powder cancer claims; Soaring injectable insulin prices shock patients; and more...

Johnson & Johnson ($JNJ) CEO Alex Gorsky and his wife have a new Manhattan pad. The Gorskys laid out $9 million--more than the asking price--for a condo on Riverside Drive, the New York Post reports. The J&J chief recently caught fire for his pay package from an activist investor; in 2014, his compensation amounted to $24.99 million, putting him 8th on FiercePharma's highest-paid list. J&J's headquarters is in New Brunswick, NJ. Story | More | CEO pay ranking

@FiercePharma: Stem cell therapy developed to treat dental disease in cats could also help people. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Teva is adding 20 jobs at UK plant, but only after cutting 80 as it looks for different skills. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa. Report from FiercePharmaMarketing | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) has begun trial Tuesday over claims its talcum powder gave some women cancer. Report

> Prices for injectable insulins have soared over the past few years, leaving patients surprised and frustrated. More

> Drug companies around the world are funneling money into programs aimed at improving patient adherence. More

> India's Aurobindo Pharma has won an FDA green light to market its Isosulfan Blue Injection, 1%, which is used in lymphography procedures. Report

Medical Device News

@FierceMedDev: Next 'blow up' for Theranos? The company's latest legal hire: NYT. Article | Follow @FierceMedDev

@EmilyWFierce: Come for a story about stem cell therapy in felines. Stay for a pic of Bob the cat. More from FierceAnimalHealth | Follow @EmilyWFierce

> ViaCyte acquires J&J IP to further its quest to treat diabetes using implanted stem cells. Story

> Abbott snags CE mark for continuous glucose monitor for kids. Article

> Dx Digest: Illumina inks four genetic research deals; Trovagene makes moves in liquid biopsy with additional coverage for tests. Report

Biotech News

@FierceBiotech: FierceBiotech Radio on Gilead's wide-open future, biotech's long winter and Sanofi's ongoing makeover. More/Subscribe | Follow @FierceBiotech

@JohnCFierce: ICYMI: Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging. Article | Follow @JohnCFierce

> J&J goes all in with ViaCyte, hands over BetaLogics assets in hunt for diabetes cure. Story

> Twist Bio's hard-charging CEO hit by claims she stole Agilent's trade secrets. Report

> InflaRx starts preparation for PhIIb septic organ dysfunction trial after clearing safety study. Article

CRO News

> Onyx Scientific expands again as GMP demand grows. Article

> Catalent invests more in Asia, beefing up a Singapore supply outpost. More

> Fox Foundation backs Evotec's Parkinson's project. Report

> French CRO Novasep bulks up its manufacturing services in the U.S. Story

> BioClinica launches new research offering for marketed meds. Article

Pharma Manufacturing News

> Pakistani man charged with bringing counterfeit drugs into U.S. Report

> Ipca's small-scale API producer in U.K. expanding. Story

> Sanofi commits to developing Zika vax while other big players will evaluate. Item

> Valeant's Bausch + Lomb recalls more than 1M bottles of eye med. More

> Sanofi says job cuts in France should not involve plant closures. Article

Pharma Asia News

> Japan's Daiichi Sankyo joins clinical trial data request system. News

> Pfizer's busy Q4 in emerging markets a prelude for the big show. More

> BeiGene comes in at top end of range in Nasdaq IPO, raising $158.4M. Report

> Asia included in Zika virus warning zone as drugmakers ponder vaccines. Story

> GSK's CEO says it's 'difficult to understand how company is doing.' Article

And Finally... Sen. Ted Cruz (R-TX) wants to change the way the FDA approves new meds. More

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.